Cargando…

Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan

While efficient and less onerous for the industry, the globalization of clinical drug development may lead to limited efforts to optimize drugs for regional conditions. We examined the association between clinical development pathways, approved doses, and postmarketing safety risks in Japan for 135...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, TK, Ono, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504476/ https://www.ncbi.nlm.nih.gov/pubmed/28371388 http://dx.doi.org/10.1111/cts.12462

Ejemplares similares

Analysis of Global Drug Development Pathways and Postmarketing Safety in Japan: Local Studies May Reduce Drug‐Related Deaths
por: Okubo, Tomoko Kawamura, et al.
Publicado: (2019)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999–2019
por: Nakao, Minami, et al.
Publicado: (2022)

Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan
por: Kondo, Hideyuki, et al.
Publicado: (2021)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
por: Lu, Dan, et al.
Publicado: (2016)

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Publicado: (2018)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Postmarket Safety Surveillance of Delayed Complications for Recent FDA-Approved Hyaluronic Acid Dermal Fillers
por: Cohen, Joel L., et al.
Publicado: (2022)

Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan
por: NISHIKAWA, Ryo, et al.
Publicado: (2021)

A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes
por: Hoffman, Keith B., et al.
Publicado: (2015)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States
por: Hoshino, Yuko, et al.
Publicado: (2022)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
por: Misu, Takashi, et al.
Publicado: (2018)

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
por: Zeitoun, Jean-David, et al.
Publicado: (2017)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery
por: Kuroda, Yasufumi, et al.
Publicado: (2013)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Exploratory analysis of comparative clinical trials used for marketing approval in patients with type 2 diabetes in Japan
por: Kaneko, Reina, et al.
Publicado: (2019)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan
por: Watanabe, Tatsuya, et al.
Publicado: (2016)

Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan
por: Takahashi, Shoko, et al.
Publicado: (2016)

Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan
por: Kubota, Sachie, et al.
Publicado: (2016)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
por: Rathi, Vinay K., et al.
Publicado: (2020)

Effectiveness and safety of an extended‐release tablet of sodium valproate for the prophylactic treatment of migraine: Postmarketing surveillance in Japan
por: Takeshima, Takao, et al.
Publicado: (2016)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada, Eiji, et al.
Publicado: (2015)

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018
por: Fan, Min, et al.
Publicado: (2022)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Lifecycle management of orphan drugs approved in Japan
por: Seki, Kiyoshi, et al.
Publicado: (2022)

Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network
por: Ferris, Lorraine E, et al.
Publicado: (2010)

Use of National Database of Health Insurance Claims and Specific Health Checkups for examining practical utilization and safety signal of a drug to support regulatory assessment on postmarketing drug safety in Japan
por: Shida, Haruka, et al.
Publicado: (2023)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_suiv4u39ju46o80vtd79i9db80